UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/510,386	10/04/2004	Jens Tonne Andersen	10294.204-US	9551
	7590 02/26/200 NORTH AMERICA,	EXAMINER		
500 FIFTH AVI	•	VOGEL, NANCY S		
SUITE 1600 NEW YORK, NY 10110			ART UNIT	PAPER NUMBER
			1636	
		. 11 2000		
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 DA	AYS	02/26/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)				
Office Action Summary		₀ 10/510,386	ANDERSEN ET	ANDERSEN ET AL.			
		Examiner	Art Unit				
		Nancy T. Vogel	1636				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR RECHEVER IS LONGER, FROM THE MAILING resions of time may be available under the provisions of 37 CFI SIX (6) MONTHS from the mailing date of this communication of period for reply is specified above, the maximum statutory pere to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS CON R 1.136(a). In no event, howeve it is in the control of the co	IMUNICATION. r, may a reply be timely filed ((6) MONTHS from the mailing date of this ecome ABANDONED (35 U.S.C. § 133).	,			
Status							
1)	Responsive to communication(s) filed on _						
2a)□	•	—— This action is non-final.					
3) 🔲	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Exparte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) 🖂	Claim(s) 23-42 is/are pending in the application	ation.					
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)	5) Claim(s) is/are allowed.						
6)							
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) 23-42 are subject to restriction an	d/or election requireme	ent.				
Applicati	ion Papers						
	The specification is objected to by the Exan	niner					
,	The drawing(s) filed on is/are: a)		ted to by the Examiner				
.0,	• • • • • • • • • • • • • • • • • • • •	•					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
,—	ınder 35 U.S.C. § 119						
	•						
• —	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)	a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	t(s)						
_	ce of References Cited (PTO-892)		terview Summary (PTO-413)				
	ce of Draftsperson's Patent Drawing Review (PTO-948		aper No(s)/Mail Date				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application Other:							
•							

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Groups I-124, claim(s) 23-42, drawn to a Bacillus licheniformis mutant host cell mutated in at least one gene encoding one or more secreted polypeptide which is at least 80% identical to the polypeptide shown in SEQ ID NO:2, and process for producing a product of interest comprising cultivating said host cell for production of the at least one product, limited to one of SEQ ID NO:2-248.

The inventions listed as Groups 1-124 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each group is directed to a mutant having a mutation in a gene which has no structural similarity to any of the other genes, therefore the groups do not share a special technical feature is different and restriction is proper.

Note, this restriction to examination of a single sequence is due to the now very high and undue burden for examining more than one sequence which is caused by the continued exponential increase of size of the sequence databases to be searched for each sequence, resulting in a corresponding increase in computer search time and examiner time for reviewing the computer search results. Therefore, the limited resources of the Office no longer permit examination of more than one sequence in an application. Note: the non-standard format of this restriction, separating the inventions into multi-invention groups drawn to independent or distinct types of products and

Art Unit: 1636

methods, followed by an election of a single invention drawn to one sequence within the elected multi-invention group, was done for the sake of compactness of the communication and clarity, instead of using the more standard format setting forth each separate invention drawn to each separate sequence which would require a much longer communication.

Note: although the claims recite "the polypeptides shown in SEQ ID NO:s 2 to 248", it is noted that only the even numbered SEQ ID NOs disclose polypeptides, while the odd number sequences recite polynucleotides. Therefore, it is assumed that the even number sequences are intended.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

Art Unit: 1636

unpatentable over the prior art, the evidence or admission may be used in a rejection

under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy T. Vogel whose telephone number is (571) 272-0780. The examiner can normally be reached on 6:30 - 3:00, Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D. can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

2/5/07

Page 5